Dovetail Genomics, Goenomics GmbH Partnership, Danaher Acquires Genedata, Andelyn Biosciences License Agreement With Broad Institute, More

By Bio-IT World Team  

August 28, 2024 | Dovetail Genomics has formed a partnership with Goenomics GmbH to deliver an enhanced genome assembly service with the fastest turnaround time and most complete annotation available in the industry; Genedata has been acquired by Danaher; Andelyn Biosciences has entered into a License Agreement with the Broad Institute of MIT and Harvard to expand its AAV Curator Platform offering to include MyoAAV plasmids; and more. 

Dovetail Genomics announced a new strategic partnership with Goenomics GmbH. This partnership aims to deliver an enhanced genome assembly service with the fastest turnaround time and most complete annotation available in the industry. Under this partnership, Goenomics will provide advanced annotation services, significantly improving the speed, and expanding the portfolio of Dovetail's genome annotation offerings. Leveraging Goenomics' newly developed, proprietary algorithm for homology-based gene reconstruction, this partnership will ensure that researchers receive reliable and comprehensive annotation results for genome sizes up to 1GBp in just three weeks. This enables researchers to obtain rapid data, stay on schedule, and even accelerate their research timelines. Press release. 

Genedata has been acquired by Danaher. Genedata’s offerings are expected to add to Danaher’s broad workflow solutions that help accelerate the speed of drug discovery, development, and manufacturing for critical new therapies. Over the past several years, Genedata and Danaher have engaged in several successful collaborations. Press release. 

ATUM has launched the CHO-K1-derived discoCHO cell line for transient protein production. With the launch of CHO-K1-derived discoCHO for robust transient productivity in combination with the existing miCHO-GS cell line (derived from the same CHO-K1 host) for stable biologics production, ATUM’s platform now provides a fast, productive, and predictable ecosystem bridging early discovery to commercialization. ATUM will be able to customers step-by-step, from electronic sequence and design through early-stage protein production and detailed analytics. Press release.  

Verisense announced that their Digital Biobank, with data from over one million people, is open for business. The Digital Biobank includes specific medical data which can be used to identify algorithms and digital biomarkers, allowing for comparisons between data to show emerging trends for specific diseases. The data collected come from measurements such as heart rate, respiration, blood pressure, accelerometry, electrocardiogram photoplethysmography, polysomnography, electromyography, electrooculography and galvanic skin response sensors. Press release. 

Scale Biosciences announced the launch of the “100 Million Cell Challenge,” a global initiative aimed at pushing the boundaries of single-cell genomics research, in collaboration with Ultima Genomics and NVIDIA. This first-of-its-kind program calls on researchers worldwide to submit proposals for large-scale single cell projects, with the goal of collectively analyzing 100 million cells or more across diverse biological systems and research areas. Key features of the Challenge include minimum project size of one million cells, with no maximum limit; collaboration with industry-leading partners for sequencing and data analysis services; and substantially subsidized costs for library preparation and sequencing services. Press release. 

Evotec SE has entered a strategic partnership with Bristol Myers Squibb, further bolstering the joint pipeline of advanced neuroscience programs. Evotec received a $25 million payment to progress further research. Evotec and Bristol Myers Squibb entered their strategic neuroscience collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. The progress announced here leverages Evotec’s PanOmics platform in conjunction with patient-derived disease models, which is one of the largest and most sophisticated platforms in the industry. Press release. 

Andelyn Biosciences has entered into a License Agreement with the Broad Institute of MIT and Harvard to expand its AAV Curator Platform offering to include MyoAAV plasmids. Developed by researchers at the Broad Institute, this new family of plasmids produces adeno-associated viruses that are 10 times more efficient in reaching muscle tissue than wild-type vectors, while also de-targeting the liver. With more precise targeting of muscle tissue, research shows MyoAAV-delivered therapies may require lower dosing. The License Agreement allows Andelyn to use the MyoAAV plasmids to perform research and development services for its clients who are developing gene therapies to screen potential candidates at Andelyn and to perform scale-up and pre-clinical development work in preparation for IND-enabling studies. The Agreement also permits Andelyn to sublicense the MyoAAV plasmids to its clients for internal research purposes.  Press release.   

Twist Bioscience and bitBiome announced the launch of a joint Transaminase Enzyme Screening Kit, which is a curated collection of 48 highly diverse transaminase enzymes ready for in-house screening and evaluation. This kit features a unique set of transaminases that can be used by labs and pharmaceutical companies to efficiently implement improved enzymes for biocatalysis, particularly for the synthesis of active pharmaceutical ingredients (APIs). Press release. 

Rejuvenate Biomed and SAS have entered a partnership to develop a user-friendly drug repurposing discovery tool for researchers and scientists to uncover medically relevant insights about drugs, diseases, and biological networks, through fast and systematic explorations of hidden biological patterns. The discovery tool will be developed on SAS Viya, a powerful cloud-native artificial intelligence (AI) and data platform. The partnership will unite Rejuvenate Biomed’s clinically validated AI-driven drug discovery platform and end-to-end drug development proficiency with SAS’ decades of AI expertise. Press release. 

Sapio Sciences and Zifo announced a strategic partnership to bring best-in-class laboratory information management solutions to customers across the biotech, clinical diagnostics, and pharmaceutical industries. The partnership combines Zifo’s consulting expertise in AI & ML services with Sapio's highly configurable lab informatics platform and expertise in system design, deployment, and integration. The partnership will also see Sapio certify Zifo engineers to ensure joint customers can access highly skilled engineers and solution consultants when deploying Sapio solutions. Press release. 

Labcorp announced an expanded collaboration with Ultima Genomics to utilize its UG 100TM sequencing solution and ppmSeq technology to explore new whole genome sequencing (WGS) clinical applications, including molecular residual disease (MRD) in patients with early-stage solid tumor cancers. Press release.